Astra Zeneca Acquires Eso Biotec in $1B Deal for Cancer Treatment Advancements

1 Billion Dollar Transaction Astra Zeneca Completes Acquisition of Cell Therapy Firm Eso Biotec

2025-05-20 Source: Astra Zeneca 1 min Reading Time

Related Vendors

AstraZeneca

Italvacuum, Srl

Frewitt fabrique de machines SA

ProMinent GmbH

In a 1 billion dollar deal, Astra Zeneca acquires Belgium-based Eso Biotec. The deal brings cutting-edge technology aimed at making cancer treatment faster and more accessible.

The deal with Eso Biotec brings cutting-edge technology into Astra Zeneca’s pipeline, paving the way for faster, more accessible in vivo cancer treatments.(Source: Catharina Fyrberg/ Astra Zeneca) — The deal with Eso Biotec brings cutting-edge technology into Astra Zeneca’s pipeline, paving the way for faster, more accessible in vivo cancer treatments.
(Source: Catharina Fyrberg/ Astra Zeneca)

Pharmaceutical company Astra Zeneca announced the successful completion of the acquisition of Eso Biotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity. Under the terms of the agreement, Astra Zeneca has acquired all outstanding equity of Eso Biotec for a total consideration of up to 1 billion dollars, on a cash and debt free basis. This includes an initial payment of 425 million dollars, and up to 575 million dollars in contingent consideration based on development and regulatory milestones. As a result of this acquisition, Eso Biotec has become a wholly owned subsidiary of Astra Zeneca, with operations in Belgium.

The Eso Biotec Engineered Nano Body Lentiviral (Enabl) platform empowers the immune system to attack cancers and could offer better access to transformative cell therapy treatments delivered in just minutes rather than the current process which takes weeks. Enabl uses highly targeted lentiviruses to deliver genetic instructions to specific immune cells, such as T cells, which programme them to recognise and destroy tumour cells for cancer treatment or autoreactive cells for potential use in immune-mediated diseases. This approach enables cell therapies to be administered through a simple IV injection and without the need for immune cell depletion.

(ID:50427349)

Subscribe to the newsletter now

Don't Miss out on Our Best Content

Business E-mail

Please enter a valid mailadress.

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy. The consent declaration relates, among other things, to the sending of editorial newsletters by email and to data matching for marketing purposes with selected advertising partners (e.g., LinkedIn, Google, Meta)

Date: 08.12.2025

Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.

Consent to the use of data for promotional purposes

I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planck-Str. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here

Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.

Additionally, my consent also includes the processing of my email address and telephone number for data matching for marketing purposes with select advertising partners such as LinkedIn, Google, and Meta. For this, Vogel Communications Group may transmit said data in hashed form to the advertising partners who then use said data to determine whether I am also a member of the mentioned advertising partner portals. Vogel Communications Group uses this feature for the purposes of re-targeting (up-selling, cross-selling, and customer loyalty), generating so-called look-alike audiences for acquisition of new customers, and as basis for exclusion for on-going advertising campaigns. Further information can be found in section “data matching for marketing purposes”.

In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here. This does not apply to data matching for marketing purposes.

Right of revocation

I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://contact.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.